Skip to search formSkip to main contentSkip to account menu

JNJ 26481585

Known as: HDAC Inhibitor JNJ-26481585, JNJ-26481585, JNJ26481585 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Hydroxamic AcidsQuisinostat

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Preliminary results of an open-label phase I pharmacokinetic/pharmacodynamic study of JNJ26481585: Early evidence of antitumor activity.
e13504 Background: JNJ26481585 is a novel orally active pan-histone deacetylase inhibitor (HDACI) which showed potent antitumor… 
2015
2015
JNJ-26481585 primes rhabdomyosarcoma cells for chemotherapeutics by engaging the mitochondrial pathway of apoptosis
Rhabdomyosarcoma (RMS) is a common soft-tissue sarcoma in childhood with a poor prognosis, highlighting the need for new… 
2011
2011
A first-in-human phase I study of JNJ-26481585, a novel oral histone deacetylase inhibitor (HDACi), in patients with advanced cancer with evidence of target modulation and antitumor activity.
3024 Background: JNJ-26481585 is a potent, hydroxamate, pan-HDACi with broad activity in solid and hematologic tumor models… 
2010
2010
Abstract 5441: Preclinical assessment of the HDAC inhibitor JNJ-26481585: potentin vivoactivity across a broad spectrum of human tumor xenografts
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC JNJ-26481585 is a promising “second generation… 
2010
2010
601 Comparative tissue distribution of the HDAC inhibitor JNJ-26481585
2008
2008
Antileukemia Activity of JNJ-26481585, a Potent Second-Generation Histone Deacetylase Inhibitor
Background: Histone Deacetylases (HDACs) play key roles in tumor cell proliferation, survival and angiogenesis. HDAC inhibitors… 
2008
2008
Analysis of Patients Receiving Histone Deacetylase Inhibiting Antiepileptic Agents during Radiation Treatment for Glioblastoma
2007
2007
JNJ-26481585, a novel “second-generation” oral pan-histone deacetylase (HDAC) inhibitor, shows broad-spectrum preclinical antitumoral activity against solid and hematological malignancies
A264 Histone deacetylase (HDAC) inhibitors have shown promising clinical activity in the treatment of haematological malignancies… 
2007
2007
Novel, 2 ND Generation Histone Deacetylase (HDAC) Inhibitor JNJ-26481585 Exhibits Potent Antitumor Activity Against Chronic Lymphocytic Leukemia Cells In-Vitro and Ex-Vivo .
Chronic lymphocytic leukemia (CLL), the most frequent lymphoproliferative disease is characterized by the insidious accumulation… 
2004
2004
Purchase of Aton spotlights HDAC inhibitors
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)